Approximately 20–50% of COVID-19 hospitalized patients show alterations in coagulation tests, such as high d-dimer, prolonged PT, thrombocytopenia, and low fibrinogen levels [22], suggesting the occurrence of blood clotting activation, similar to disseminated intravascular coagulation (DIC). This evidence concerns the gene F2 and COVID-19.